The economic impact of HA-1A (Centoxin) against endotoxin.
Monoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative sepsis and/or septic shock.  However, the acquisition costs of the antibody products are expected to be in the range of $US3500 to $US4000 per course of therapy and precise identification of patients who will benefit may be difficult.  Therefore, the economic impact of these antibodies will be significant.  We have performed a model cost-effectiveness and cost-benefit analysis specific to our institution based on previously reported mortality figures.  Our data suggest that the cost-effectiveness of HA-1A (Centoxin) will be comparable with that of a variety of commonly used medical interventions, but will produce an incremental increase in costs of at least $US7000 per patient because of the acquisition cost of the drug, as well as an increase in numbers of survivors whose hospitalisation will be prolonged.
University of California, Los Angeles, Center for the Health Sciences.
S L
SL
Barriere
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004731:Endotoxins / Q000009:adverse effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000401:mortality; D017048:Health Care Costs; D006801:Humans; D007902:Length of Stay; D012189:Retrospective Studies; D012772:Shock, Septic / Q000188:drug therapy / Q000401:mortality